Endpoint selection determines whether an outpatient antiviral program can support approval. Sponsors designing trials in COVID-19, influenza, and RSV must decide early whether to pursue a hospitalization-or-death composite or a symptom-based patient-reported outcome, and how much weight virologic measures such as viral load reduction or shedding duration can carry. Getting this wrong at the protocol stage is expensive to correct after enrollment begins.
The analysis below traces the endpoints FDA has accepted across outpatient respiratory antiviral reviews, drawing on approval documents, review memoranda, and agency guidance. It covers how each endpoint family was defined and measured, the populations they were applied to, and the reasoning FDA applied when virologic and clinical results pointed in different directions.
Want Rhizome's help on your own question? Try it for free.
Efficacy endpoints for outpatient COVID-19 and respiratory antivirals: how FDA weighs virologic measures against clinical outcomes
Across two decades of respiratory antiviral review, FDA has held a consistent line: approval rests on a direct clinical endpoint that captures how patients feel, function, or survive, and virologic measures such as viral load or duration of shedding are treated as secondary, supportive evidence of antiviral activity rather than as approvable surrogates for clinical benefit. That principle predates COVID-19 in the influenza program and was carried directly into the review of outpatient SARS-CoV-2 antivirals. The sections below set out the specific endpoints FDA accepted product by product and the reasoning it applied when virologic and clinical data diverged.
The two accepted outpatient endpoint families
For nonhospitalized (outpatient) respiratory antiviral treatment, FDA has accepted two clinical endpoint constructs, chosen according to the target population and the drug's expected effect:
- A hospitalization-or-death composite, used for higher-risk outpatients where the value proposition is preventing progression to severe disease. In COVID-19 guidance FDA lists all-cause mortality and need for hospitalization among acceptable clinical outcomes, alongside respiratory-failure outcomes and ordinal clinical-status scales 91.
- Sustained symptom alleviation or resolution, defined through a patient-reported outcome instrument as no key symptom exceeding a prespecified threshold sustained over a clinically meaningful period, used where the benefit is faster clinical recovery 91.
The influenza program uses the parallel symptom construct: for acute uncomplicated influenza in adults, FDA recommends time to a pre-defined level of symptom improvement/alleviation as the primary endpoint, analyzed primarily in laboratory-confirmed cases 192021.
Outpatient COVID-19: hospitalization/death carried the approvals
Paxlovid (nirmatrelvir/ritonavir). In the pivotal EPIC-HR trial, the primary efficacy endpoint was the proportion of participants with COVID-19-related hospitalization or death from any cause through Day 28 in the modified intent-to-treat population, with the primary estimand restricted to patients treated within 3 days of symptom onset 3345. Symptom endpoints were positioned below the composite: time to sustained alleviation of all targeted signs and symptoms through Day 28 was a key secondary endpoint, with sustained resolution and individual-symptom measures as further secondaries 33. When the sponsor sought to extend the drug's story into standard-risk patients, EPIC-SR used time to sustained alleviation of all targeted symptoms through Day 28 as its primary endpoint, and FDA reported that this primary endpoint was not met 484944.
FDA also flagged interpretive limitations of the symptom data that reinforced its preference for the hospitalization/death outcome: missing diary data with complex causes, an alleviation definition sensitive to baseline symptom severity, and the fact that fewer hospitalization/death events in the treatment arm mechanically influenced symptom comparisons because such events counted as failures. The agency viewed symptom-diary data as potentially less robust and interpretable than the hospitalization/death data 4640.
Remdesivir (Veklury), outpatient PINETREE trial. The primary efficacy endpoint was the composite of COVID-19-related hospitalization (at least 24 hours of acute care) or all-cause death through Day 28, analyzed as a time-to-event outcome 7185. This mirrors the Paxlovid construct and confirms the hospitalization/death composite as FDA's accepted primary endpoint for higher-risk outpatients.
Molnupiravir (Lagevrio) was authorized only under an Emergency Use Authorization and never received NDA approval; its MOVe-OUT trial used the same construct, with hospitalization or death through Day 29 as the primary endpoint.
Virologic measures in COVID-19: activity signals, not surrogates
The COVID-19 reviews are notable because they show FDA acting on its stated skepticism toward viral load even when the virologic data were unhelpful to the sponsor, without letting that undermine the clinical conclusion.
In both EPIC-HR and EPIC-SR, viral titers by RT-PCR in nasal swabs were listed among additional/secondary efficacy endpoints, not primary or key secondary clinical endpoints 3349. Critically, FDA reported that post-treatment viral-RNA rebound observed in EPIC-HR was not associated with the primary clinical outcome of hospitalization or death through Day 28, and it did not treat viral load as a validated surrogate for clinical benefit 334739.
The remdesivir outpatient review is the clearest statement of the principle. The key secondary virologic endpoint, time-weighted average change in nasopharyngeal viral load from baseline through Day 7, showed no meaningful between-group difference (least-squares mean difference 0.07 log10 copies/mL; p=0.43) 7579. FDA nonetheless concluded that the clinical endpoint, not upper-respiratory viral load, was the relevant evidence of benefit: nasopharyngeal viral load was deemed an inadequate surrogate for remdesivir efficacy, and the absence of an observed virologic effect did not limit the clinical efficacy conclusion 79. The virology review reached the same conclusion, finding no detectable effect on nasopharyngeal viral RNA and stating that such RNA measures may not be an appropriate surrogate for the drug's antiviral activity 78.
Influenza: time to symptom alleviation is the anchor
The influenza antiviral program is where this endpoint hierarchy was first established, and it remains the template.
Baloxavir (Xofluza). In the pivotal uncomplicated-influenza trials in otherwise healthy patients, the primary efficacy endpoint was time to alleviation of influenza symptoms (TTAS) versus placebo, requiring all seven symptoms (cough, sore throat, headache, nasal congestion, feverishness/chills, muscle or joint pain, and fatigue) to be rated none or mild for approximately one day 54, consistent with FDA guidance and prior antiviral registration trials 63. Virologic outcomes (viral culture/RT-PCR positivity, viral titer/RNA change, and time to cessation of shedding) were prespecified as secondary, including a "key secondary virologic" endpoint, but the primary comparison and statistical powering rested on TTAS 545564. The divergence is instructive. In the otherwise-healthy pivotal trial, baloxavir shortened median TTAS to roughly 54 hours versus 80 hours on placebo 68. In the high-risk study review, although baloxavir reduced infectious-virus shedding, viral-RNA negativity was not meaningfully accelerated overall, illustrating that virologic findings did not override the clinical endpoint 56.
Oseltamivir (Tamiflu). For uncomplicated influenza in adults and adolescents, the primary endpoint was time to alleviation of all seven influenza symptoms, described in labeling as time to improvement until nasal congestion, sore throat, cough, aches, fatigue, headache, and chills/sweats were all rated none or mild 311. In children aged 1 to 12 years, the primary endpoint was a composite "time to freedom from illness" (cough and coryza alleviation, fever resolution, and parent-rated return to normal health and activity) 8. Virologic measures ranked even lower here: in the pediatric treatment protocol, viral shedding, time to cessation of shedding, viral-titer AUC, and resistance assessment were designated tertiary efficacy parameters 6.
Why virologic endpoints do not qualify as the primary measure
FDA's influenza guidance sets out the reasoning that also governs the COVID-19 and broader respiratory antiviral programs. The agency does not consider viral burden or viral shedding a reliable surrogate for important clinical outcomes because they are not sufficiently standardized or characterized in relation to those outcomes 23. Its specific objections are:
- No established predictive relationship between the magnitude or timing of viral reduction and how patients feel, function, or survive 19.
- Assay and sampling variability: relevant sampling sites, collection methods, and assays are not established, and virologic results vary substantially across methods 19.
- No trial-efficiency advantage: because clinical and virologic changes occur on the same time scale in influenza, virologic endpoints neither shorten trials nor distinguish therapies more readily than direct clinical outcomes 19.
FDA states that viral titer reduction in nasal wash may measure virologic response but should not be used as the primary endpoint to support drug approval; where virologic data are collected, the relationship between virologic measures and the primary clinical endpoint should be assessed using all available data 31. Virologic measures do have a defined role earlier in development: in phase 2 dose-ranging, viral-shedding duration or quantitative change from baseline, combined with clinical-symptom trends, can help select doses for phase 3 26, and viral cultures obtained at baseline and appropriate intervals support secondary analyses, evaluability, and resistance and transmission assessment 1925.
RSV and other respiratory viruses: viral load for activity, clinical outcomes for benefit
The same logic extends to the wider respiratory antiviral space. FDA's draft RSV treatment guidance encourages exploring both virologic and clinical endpoints in early development. In experimentally infected healthy adults, endpoints may include changes in RSV viral load, RSV-specific symptom scores, and nasal mucus weight; in naturally infected immunocompromised or older adults, phase 2 endpoints may include RSV viral load change, clinical symptom scores, duration of hospitalization, and other markers of disease progression or resolution 29. But FDA frames viral load as an antiviral-activity or pharmacodynamic measure rather than a stand-alone surrogate for clinical benefit: challenge studies, where illness is generally mild and limited to the upper respiratory tract, may be useful only to demonstrate antiviral activity and are less suitable for demonstrating clinical benefit, whereas trials in naturally infected patients with clinically significant, potentially lower-respiratory-tract disease are more likely to show a clinical treatment benefit 29. Trials should be randomized, double-blind, and controlled, with blinding especially important because these endpoints can be subjective 30. The bottom line across these guidances is that viral-load reduction can support dose selection, exposure-response, and proof of antiviral activity, but approval-supporting efficacy should rest on meaningful clinical outcomes unless a surrogate relationship has been formally established 29312032.
What this means for antiviral development programs
For sponsors designing outpatient respiratory antiviral trials, the accepted primary endpoint depends on the population and the claim: a hospitalization-or-death composite through Day 28 for higher-risk patients (Paxlovid EPIC-HR, remdesivir PINETREE) 3371, or a validated, PRO-based sustained symptom alleviation/resolution endpoint for recovery claims (COVID-19 outpatients, uncomplicated influenza TTAS) 9119543. Virologic endpoints should be built in as secondary and exploratory measures to demonstrate antiviral activity, characterize resistance, and support dose selection, but a program that relies on viral-load reduction as its primary evidence of benefit runs directly against FDA's stated position that the virologic-to-clinical relationship for these viruses is not established. The remdesivir outpatient review is the cautionary example in reverse: a clean clinical win despite a null virologic result, precisely because FDA had never elevated nasopharyngeal viral load to surrogate status 7978.